Inhibrx Biosciences, Inc.
INBXNasdaqCIK 2007919HealthcareFiscal year ends Dec 31
Reports and events: 43 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2821:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002007919-26-000050 |
| 2026-09-0820:01 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0002007919-26-000047 |
| 2026-08-1320:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002007919-26-000044 |
| 2026-08-1320:04 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0002007919-26-000042 |
| 2026-07-1620:06 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002007919-26-000037 |
| 2026-06-1520:06 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0002007919-26-000033 |
| 2026-06-0320:02 ET | 8-K | 5.07 Shareholder vote results | 0002007919-26-000030 |
| 2026-05-1420:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002007919-26-000028 |
| 2026-05-1420:02 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0002007919-26-000027 |
| 2026-05-1120:02 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0002007919-26-000020 |
| 2026-04-2320:05 ET | DEF 14A | Proxy statementPeriod 2025-12-31 | 0002007919-26-000014 |
| 2026-04-2120:04 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0002007919-26-000010 |
| 2026-03-1920:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002007919-26-000007 |
| 2026-03-1920:00 ET | 10-K | Annual reportPeriod 2025-12-31 | 0002007919-26-000006 |
| 2026-02-2314:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002007919-26-000002 |
| 2025-12-1622:00 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0002007919-25-000097 |
| 2025-11-1423:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002007919-25-000094 |
| 2025-11-1422:59 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0002007919-25-000093 |
| 2025-10-2320:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0002007919-25-000089 |
| 2025-08-1320:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002007919-25-000083 |
| 2025-08-1320:03 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0002007919-25-000081 |
| 2025-05-2820:03 ET | 8-K | 5.07 Shareholder vote results | 0002007919-25-000063 |
| 2025-05-1420:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002007919-25-000057 |
| 2025-05-1420:09 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0002007919-25-000056 |
| 2025-04-1620:49 ET | DEF 14A | Proxy statementPeriod 2024-12-31 | 0002007919-25-000043 |
| 2025-04-0120:13 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0002007919-25-000028 |
| 2025-03-1720:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002007919-25-000020 |
| 2025-03-1720:03 ET | 10-K | Annual reportPeriod 2024-12-31 | 0002007919-25-000019 |
| 2025-02-2621:26 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0002007919-25-000015 |
| 2025-02-2621:16 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0002007919-25-000012 |
| 2025-01-2122:03 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0002007919-25-000007 |
| 2025-01-1321:18 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002007919-25-000003 |
| 2024-11-1421:25 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002007919-24-000060 |
| 2024-11-1421:02 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0002007919-24-000058 |
| 2024-11-0421:36 ET | 8-K | 8.01 Other events | 0002007919-24-000054 |
| 2024-08-1320:09 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002007919-24-000031 |
| 2024-08-1320:03 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0002007919-24-000029 |
| 2024-06-1720:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002007919-24-000016 |
| 2024-06-1121:11 ET | S-1 | Registration statement | 0002007919-24-000011 |
| 2024-06-0300:45 ET | SC 13D | Ownership report, active investor | 0000950142-24-001549 |
| 2024-06-0300:43 ET | SC 13D | Ownership report, active investor | 0000950142-24-001548 |
| 2024-05-3020:11 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-066645 |
| 2024-05-2420:21 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-24-065140 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.